Literature DB >> 16299279

Conjugates of group A and W135 capsular polysaccharides of neisseria meningitidis bound to recombinant Staphylococcus aureus enterotoxin C1: preparation, physicochemical characterization, and immunological properties in mice.

Zhigang Jin1, Gregory A Bohach, Joseph Shiloach, Scott E Norris, Darón I Freedberg, Claudia Deobald, Bruce Coxon, John B Robbins, Rachel Schneerson.   

Abstract

Neisseria meningitidis groups A (GAM) and W135 capsular polysaccharides (CPs) were bound to recombinant Staphylococcus aureus enterotoxin C1 (rSEC). The CPs were activated with 1-cyano-4-dimethylaminopyridinium tetrafluoroborate and then bound to adipic acid dihydrazide derivatives of rSEC. Syntheses were conducted with native GAM CP (GAMP), W135 CP (W135P), and ultrasonicated or hydrazine-treated W135P at various concentrations of reactants, pHs, and ionic strengths. The conjugates were characterized by compositional and serologic analyses, high-performance size-exclusion chromatography with multi-angle laser light scattering detection, and immunogenicity in 5- to 6-week-old mice. Conjugates injected subcutaneously in phosphate-buffered saline elicited immunoglobulin G (IgG) responses against their respective CPs and rSEC, whereas GAMP and W135P alone did not induce detectable CP antibodies. The O-acetyl content of W135P was low, and its removal had no adverse effect upon the conjugate's immunogenicity. Reduction of the molecular size of W135P by treatment with hydrazine improved the immunogenicity of W135P-rSEC. IgG anti-CP elicited by the conjugates showed complement-dependent bactericidal activity against their respective organisms, and IgG anti-rSEC neutralized the T-cell proliferative activity of native SEC. A bivalent formulation of GAMP-rSEC and W135P-rSEC elicited IgG anti-CP at comparable levels to those induced by the conjugates administered separately.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16299279      PMCID: PMC1307062          DOI: 10.1128/IAI.73.12.7887-7893.2005

Source DB:  PubMed          Journal:  Infect Immun        ISSN: 0019-9567            Impact factor:   3.441


  37 in total

1.  Neisseria meningitidis serogroups W135 and A were equally prevalent among meningitis cases occurring at the end of the 2001 epidemics in Burkina Faso and Niger.

Authors:  Muhamed-Kheir Taha; Isabelle Parent Du Chatelet; Martin Schlumberger; Idrissa Sanou; Saacou Djibo; François de Chabalier; Jean-Michel Alonso
Journal:  J Clin Microbiol       Date:  2002-03       Impact factor: 5.948

2.  Meningococcal disease, serogroup W135, Burkina Faso. Preliminary report, 2002.

Authors: 
Journal:  Wkly Epidemiol Rec       Date:  2002-05-03

3.  Cross-neutralization of staphylococcal and streptococcal pyrogenic toxins by monoclonal and polyclonal antibodies.

Authors:  G A Bohach; C J Hovde; J P Handley; P M Schlievert
Journal:  Infect Immun       Date:  1988-02       Impact factor: 3.441

4.  Trial of a serogroup A meningococcus polysaccharide vaccine in Nigeria.

Authors:  W R Sanborn; Z Bencić; B Cvjetanović; E C Gotschlich; T M Pollock; J E Sippel
Journal:  Prog Immunobiol Stand       Date:  1971

5.  A trial of a group A plus group C meningococcal polysaccharide-protein conjugate vaccine in African infants.

Authors:  P A Twumasi; S Kumah; A Leach; T J O'Dempsey; S J Ceesay; J Todd; C V Broome; G M Carlone; L B Pais; P K Holder
Journal:  J Infect Dis       Date:  1995-03       Impact factor: 5.226

6.  Ultrasonic irradiation of bacterial polysaccharides. Characterization of the depolymerized products and some applications of the process.

Authors:  S C Szu; G Zon; R Schneerson; J B Robbins
Journal:  Carbohydr Res       Date:  1986-09-01       Impact factor: 2.104

7.  Dosage escalation, safety and immunogenicity study of four dosages of a tetravalent meninogococcal polysaccharide diphtheria toxoid conjugate vaccine in infants.

Authors:  Margaret Rennels; James King; Robert Ryall; Thomas Papa; James Froeschle
Journal:  Pediatr Infect Dis J       Date:  2004-05       Impact factor: 2.129

8.  Evaluation of two tetravalent (ACYW135) meningococcal vaccines in infants and small children: a clinical study comparing immunogenicity of O-acetyl-negative and O-acetyl-positive group C polysaccharides.

Authors:  H Peltola; A Safary; H Käyhty; V Karanko; F E André
Journal:  Pediatrics       Date:  1985-07       Impact factor: 7.124

9.  Form variation in Escherichia coli K1: determined by O-acetylation of the capsular polysaccharide.

Authors:  F Orskov; I Orskov; A Sutton; R Schneerson; W Lin; W Egan; G E Hoff; J B Robbins
Journal:  J Exp Med       Date:  1979-03-01       Impact factor: 14.307

10.  Serogroup W-135 meningococcal disease during the Hajj, 2000.

Authors:  Jairam R Lingappa; Abdullah M Al-Rabeah; Rana Hajjeh; Tajammal Mustafa; Adel Fatani; Tami Al-Bassam; Amira Badukhan; Abdulhafiz Turkistani; Sahar Makki; Nassen Al-Hamdan; Mohamed Al-Jeffri; Yaqoub Al Mazrou; Bradley A Perkins; Tonja Popovic; Leonard W Mayer; Nancy E Rosenstein
Journal:  Emerg Infect Dis       Date:  2003-06       Impact factor: 6.883

View more
  4 in total

1.  Physical and chemical characterization and immunologic properties of Salmonella enterica serovar typhi capsular polysaccharide-diphtheria toxoid conjugates.

Authors:  Changfa Cui; Rodney Carbis; So Jung An; Hyun Jang; Cecil Czerkinsky; Shousun C Szu; John D Clemens
Journal:  Clin Vaccine Immunol       Date:  2009-11-04

2.  A Chemoenzymatic Synthon Strategy for Synthesizing N-Acetyl Analogues of O-Acetylated N. meningitidis W Capsular Polysaccharide Oligosaccharides.

Authors:  Riyao Li; Anoopjit S Kooner; Saddam M Muthana; Yue Yuan; Hai Yu; Xi Chen
Journal:  J Org Chem       Date:  2020-11-09       Impact factor: 4.354

Review 3.  Factors contributing to the immunogenicity of meningococcal conjugate vaccines.

Authors:  Michael Bröker; Francesco Berti; Paolo Costantino
Journal:  Hum Vaccin Immunother       Date:  2016-03-02       Impact factor: 3.452

Review 4.  Role of O-Acetylation in the Immunogenicity of Bacterial Polysaccharide Vaccines.

Authors:  Francesco Berti; Riccardo De Ricco; Rino Rappuoli
Journal:  Molecules       Date:  2018-06-02       Impact factor: 4.411

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.